Login / Signup

Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients.

Michelle TewPhilip ClarkeKarin ThurskyKim Dalziel
Published in: PharmacoEconomics (2020)
There is scope for including costs beyond intervention costs in economic evaluations. The inclusion of future medical costs can result in markedly different cost-effectiveness results, leading to higher ICERs in a cancer population, with possible implications for funding decisions.
Keyphrases
  • healthcare
  • randomized controlled trial
  • current status
  • squamous cell
  • childhood cancer